Chair:

Dr. Eskild Petersen, Principal Investigator, Aarhus University Hospital – Skejby, Denmark

13:30-13:50

Title: Chinese HB Vaccine R&D and Production
Dr. Yan Wang, Professor, Shenzhen Polytechnic, China

13:50-14:10

Title: Antibody-mediated Protective Immunity against Intracellular Bacterial Pathogens
Dr. Guoquan Zhang, Assistant Professor, University of Missouri-Columbia, USA

14:10-14:30

Title: Salmonella Typhi Vaccine
Dr. Huoying Shi,Research Associate, Arizona State University, USA

 Chair:

Dr. Eskild Petersen, Principal Investigator, Aarhus University Hospital – Skejby, Denmark

14:30-14:50

Title: Toxoplasma Gondii: A Model Organism for Development of Vaccines against Apicomplexan Protozoan Parasites
Dr. Eskild Petersen, Principal Investigator, Aarhus University Hospital – Skejby, Denmark

14:50-15:10

Title: Blood Dendritic Cell Precursors: the Important Targets for the New Generation of Vaccines
Dr. Chunfeng Qu, Professor, Chinese Academy of Medical Sciences, China

15:10-15:30

Coffee Break

 Chair:

Dr Louis-P. Vézina, Chief Scientific Officer, Medicago Inc, Canada

 Co-Chair:

Dr. Vidadi M. Yusibov, Executive Director, Fraunhofer USA Center for Molecular Biotechnology, USA

15:30-15:50

Title: VLP Express: a Discovery HT Platform for New-generation Vaccines Based on VLPs
Dr Louis-P. Vézina, Chief Scientific Officer, Medicago Inc, Canada

15:50-16:10

Title: Rapid Response Technology for Vaccine Development
Dr. Vidadi M. Yusibov, Executive Director, Fraunhofer USA Center for Molecular Biotechnology, USA

16:10-16:30

Title: The Characterization of Protein by Novel GPC/SEC Detection Technology
Dr. Hui Ning, Product Specialist, Nanometrics, Malvern Instruments China, China

16:30-16:50

Title: Production of FMDV Virus-like Particles by a SUMO Fusion Protein Approachin Escherichia Coli
Dr.Ting-Fang Wang, Associate Research Fellow, Institute of Molecular Biology, Taiwan

16:50-17:10

Title: Novel Technologies for Mycoplasma Lipid-antigen Discovery and Vaccine Development
Dr. Kazuhiro Matsuda, Invited Senior Research Scientist, National Institute of Advanced Industrial Science and Technology (AIST), Japan

17:10-17:30

Title: A Role for Immunoinformatics in Livestock T-cell Vaccines
Dr. Vish Nene, Director, Biotechnology Theme, International Livestock Research Institute, Kenya

 Chair:

Dr. Adrian Bot, Vice President, Scientific Management, MannKind Corp., USA

 Co-Chair:

Dr. Daniel Scherman, Professor& Director, Laboratory of Pharmacology and Chemical Genetics, INSERM, France

08:10-08:30

Keynote Speech:
Title: Technologies for the Discovery and Development of New Vaccines
Dr. Jeffrey B. Ulmer, Global Head, External Research, Novartis Vaccines & Diagnostics, USA

08:30-08:50

Title: Optimisation of Intradermal DNA Electrotransfer for Immunisation
Dr. Daniel Scherman, Professor& Director, Laboratory of Pharmacology and Chemical Genetics, INSERM, France

08:50-09:10

Title: Intra-lymph Node DNA and Peptide Vaccination Elicit Distinct Transcriptional Programs in CD8+T Cells, with Implication to Vaccine Design
Dr. Adrian Bot, Vice President, Scientific Management, MannKind Corp., USA

09:10-09:30

Title:Enhanced Humoral and Cell-mediated Immunity of Human Papillomavirus DNA Vaccine Using HERV-Expressing Baculovirus Nanoparticles
Dr. Yu-Kyoung Oh, Associate Professor, Seoul National University, South Korea

09:30-09:50

Title:Genetically Engineer Salmonella to Improve DNA Vaccine Host-vector Delivery System
Dr. Wei Kong, Assistant Professor, Arizona State University, USA

09:50-10:10

10:10-10:30

Coffee Break

 Chair:

Dr. Nathalie Garcon, Vice President; Head of Global Adjuvant Center for Vaccines, GlaxoSmithKline Biologicals, Belgium

 Co-Chair:

Dr. Bror Morein, Professor, Uppsala University. Sweden

08:30-08:55

Title: The GlaxoSmithKline Adjuvant Systems in Vaccines: Achievements and Perspectives
Dr. Nathalie Garcon, Vice President, Head of Global Adjuvant Centre for Vaccine Development, GlaxoSmithKline Biologicals, Belgium

08:55-09:20

Title: Applying Advances in Immunology and Nanoparticle Technology to Develop a Novel Class of Vaccines
Dr. Grayson Lipford, Vice President of Discovery, Selecta Biosciences Inc., USA

09:20-09:45

Title: ISCOMS, Past and Latest Development
Dr. Bror Morein, Professor, Uppsala University. Sweden

09:45-10:10

Title: Development of in Vitro Dendritic Cell Based Assays for the Assessment of Vaccine Adjuvants Potential
Dr. Maria Foti, Professor, University of Milano-Bicocca, Italy

10:10-10:30

Coffee Break

10:30-10:55

Title: Genetically Engineer Salmonella Containing Monophosphoryl-lipid a to Improve Vaccine Immunogenicity and Safety
Dr. Qingke Kong, Research Fellow, Arizona State University, USA

10:55-11:20

Title: Vaccines against Glanders
Dr. David M. Waag, Microbiologist, United States Army Medical Research Institute of Infectious Diseases, USA

11:20-11:45

Title: Th17 Skewing Activity after Pulmonary Delivery of Polyelectrolyte Microcapsules
Dr. Stefaan De Koker, Post-doctoral Associate, Ghent University, Belgium

 Chair:

Dr. Kris Chadee, Professor, Department of Microbiology and Infectious Diseases, University of Calgary, Canada

 Co-Chair:

Dr. David H. Francis, Professor, South Dakota State University, USA

10:00-10:20

Title: Advances in Vaccine Development for the Parasite Entamoeba Histolytica
Dr. Kris Chadee, Professor, Department of Microbiology and Infectious Diseases, University of Calgary, Canada

10:20-10:40

Title: Piglet Model for Assessing Enterotoxigenic E. coli Vaccine Candidates
Dr. David H. Francis, Professor, South Dakota State University, USA

10:40-11:00

Title: The Importance of Mucosal Immunity in Generating Vaccines against Latent and Persistent Viral Infections
Dr. Liljana Stevceva, Associate Professor of Immunology and Microbiology, The Paul Foster School of Medicine, USA

11:00-11:20

Title: A Novel Technology for the Production of Heterologous Lipidated Immunogens in High Yield has Implications for the Field of Vaccine Design
Dr. Chih-Hsiang Leng, Associate Investigator, National Health Research Institutes, Taiwan

11:20-11:40

Title: A Novel Recombinant Lipoprotein Induces TLR2-mediated Gene Expression Profile is Different from Synthetic Tri- and Di-acyl Lipopeptide
Dr. Shih-Jen Liu, Assistant Investigator, National Health Research Institutes, Taiwan

 Chair:

Dr. Jeng-Jong Hwang, Professor, National Yang-Ming University, Taiwan

 Co-Chair:

Dr. Jishu Shi, Associate Professor, Kansas State University; Founder and CEO, Vaxiam, USA

16:20-16:45

Title: Evaluation of Cytokine-based Adjuvants Using Swine Influenza Virus Antigens
Dr. Jishu Shi, Associate Professor, Kansas State University; Founder and CEO, Vaxiam, USA

16:45-17:10

Title: DNA Vaccine in Treatment of Kidney Diseases
Dr. Guoping Zheng, Research Fellow, Centre for Transplantation and Renal Research, The University of Sydney, Australia

 Chair:

Dr. Jeng-Jong Hwang, Professor, National Yang-Ming University, Taiwan

 Co-Chair:

Dr. Jishu Shi, Associate Professor, Kansas State University; Founder and CEO, Vaxiam, USA

13:30-13:55

Keynote Speaker:
Title: Difficulties and Opportunities in Producing VLP Vaccines for Infectious Diseases and Other Disorders
Dr. Jose M. Galarza, CEO, TechnoVax, Inc., USA

13:55-14:20

Title: Maltodextrin Nanoparticles as Vectors through Biological Membranes, Applications in Prophylactic and Therapeutic Vaccine
Dr. Didier Betbeder, Professor, University of Lille2 and University of Artois, France

14:20-14:45

Title: Vaccine Delivery Needs and Challenges for Emerging Markets
Dr. Joanne Huang, Senior Scientist, Parenteral Technologies, BD Technologies, USA

14:45-15:10

Title: Nano-engineered Capsules for Efficient DC Targeting and T-cell Activation in Vitro and in Vivo
Dr. Bruno De Geest, Post-doctoral Associate, Ghent University, Belgium

15:10-15:30

Coffee Break

15:30-15:55

Title: Therapeutic Efficacy Evaluation of In-111-labeled PEGylated Liposomal Drug in Human and Murine Colon Carcinomas with Multimodalities of Molecular Imaging
Dr. Jeng-Jong Hwang, Professor, National Yang-Ming University, Taiwan

15:55-16:20

Title: A Novel Nanogel-based Delivery System for Adjuvant-free Intranasal Vaccines
Dr. Yoshikazu Yuki, Assistant Professor, The University of Tokyo, Japan

 Chair:

Dr. Kei Amemiya, Principal Investigator, US Army Medical Research Institute of Infectious Diseases, USA

 Co-Chair:

Dr. Leonard A. Smith, Senior Research Scientist (ST), Medical Countermeasures Technology, Army Medical Research and Materiel Command, USA

13:30-13:50

Title: Augmentation of the Immune Response to the Current Bipart F1-V Plague Vaccine
Dr. Kei Amemiya, Principal Investigator, US Army Medical Research Institute of Infectious Diseases, USA

13:50-14:10

Title: Finding a New Vaccine in a Ricin Protein Fold
Dr. Leonard A. Smith, Senior Research Scientist (ST), Medical Countermeasures Technology, Army Medical Research and Materiel Command, USA

14:10-14:30

Title:Recombinant Antigen Design for the Generation of Particle-bound and Targeted Vaccine Therapeutics Using the Exosome Delivery Pathway
Dr. Alain Delcayre, Senior Director of Research, BN-ImmunoTherapeutics, Inc., USA

14:30-14:50

Title: Cationic Lipids Activate TLR-dependent Cellular Cascades: Design of Adjuvants with Agonists and Antagonists Properties
Dr. Jean-Marie Ruysschaert, Professor, Center of Structural Biology and Bioinformatics, Belgium

14:50-15:10

Title: Cancer Vaccine Delivery System Using Oligomannose Coated Liposomes
Dr. Yuzuru Ikehara, Team Leader, National Institute of Advanced Industrial Technology (AIST), Japan

15:10-15:30

Coffee Break

15:30-15:50

Title: Improved Immunogenicity of Adenoviral Vaccines: Impact of Tethering the Vaccine Antigen to MHC-class II Associated Invariant Chain
Dr. Jan Pravsgaard Christensen, Associate Professor, University of Copenhagen, Denmark

15:50-16:10

16:10-16:30

Title: Immunity by Formulation Design: Customizing the Adjuvant Properties of Cationic Liposomes by Rational Combination with Immunopotentiators
Dr. Camilla Foged, Associate Professor, University of Copenhagen, Denmark

16:30-16:50

Title: Probiotics can Improve Response to Vaccination
Dr. Sarah Bourbié-Vaudaine, Research Scientist, Danone Research, France

 Chair:

Dr. Frederic J. Deschamps, Professor, Department Occupational Health, France

 Co-Chair:

Dr. Kow-Tong Chen, Professor & Chairman, Department of Public Health, College of Medicine, National Cheng Kung University, Taiwan

13:30-13:55

Title: Assessment of Protective Immunization of Workers Exposed to Hepatitis B Contamination
Dr. Frederic J. Deschamps, Professor, Department Occupational Health, France

13:55-14:20

Title: Hepatitis B and Hepatitis A Virus among Drug Users: The Roleof Vaccination
Dr. Fabio Lugoboni, Director, Azienda Ospedaliero Universitaria Pisana, Italy

14:20-14:45

Title: A Novel Therapeutic Vaccine, TG4040, for the Treatment of Chronic HCV Infection: Results from a Phase I Clinical Trial in Genotype 1 Infected Patients
Dr. Geneviève Inchauspé, Head, Department Infectious Diseases, Transgene, France

14:45-15:10

Title: Preoperative Vaccination for HBV in Polish Hospitals as a Possible Public Health Tool to Limit the Spread of an Epidemic
Dr. Maria Ganczak, Assistant Professor, Faculty of Medical Sciences, Pomeranian Medical University, Poland

15:10-15:35

Coffee Break

15:35-15:55

Title: HBV Prophylaxis after Liver Transplantation by Active Vaccination
Dr. Mikiko Ueda, Associated Director, Osakafu-Saiseikai-Noe-Hospital, Japan

 Chair:

Dr. Frederic J. Deschamps, Professor, Department Occupational Health, France

 Co-Chair:

Dr. Kow-Tong Chen, Professor & Chairman, Department of Public Health, College of Medicine, National Cheng Kung University, Taiwan

15:55-16:20

Title: Epidemiologic Features of Measles in Taiwan, 1999-2008
Dr. Kow-Tong Chen, Professor & Chairman, Department of Public Health, College of Medicine, National Cheng Kung University, Taiwan

 Chair:

Dr. Roy Curtiss III, Academician, United States National Academy of Sciences, USA

 Co-Chair:

Dr. Malabi M. Venkatesan, Task AD Group Leader, Walter Reed Army Institute of Research, USA

08:30-08:55

Title: Live Oral Shigella Vaccines, That Lack VirG(icsA), SenA(shET2-1), SenB(shET2-2) and MsbB2 Genes are Predicted to be Safer but Equally Immunogenic and Efficacious as Previously Tested Vaccine Candidates That Lack Principally the VirG(icsA) Gene
Dr. Malabi M. Venkatesan, Task AD Group Leader, Walter Reed Army Institute of Research, USA

08:55-09:20

Title: Development Antitoxin Vaccines against Enterotoxigenic Escherichia Coli (ETEC)
Dr. Weiping Zhang, Assistant Professor, South Dakota State University, USA

09:20-09:40

Coffee Break

 Chair:

Dr. Jovelle B. Laoag-Fernandez, Director, Global Medical Affairs, Adolescent and Adult Vaccines, GlaxoSmithKline Biologicals, Belgium

 Co-Chair:

Dr. Cecilia A. Ladines-Llave, Professor and Chair, Cancer Institute, Million to the University of the Philippines Manila-Philippine General Hospital, Philippines

09:40-10:05

Title: HPV-16/18 AS04-adjuvanted Vaccine, The Benefits to Girls and Women: from Clinical Trials to Clinical Practice
Dr. Jovelle B. Laoag-Fernandez, Director, Global Medical Affairs, Adolescent and Adult Vaccines, GlaxoSmithKline Biologicals, Belgium

10:05-10:30

Title: The Cecap Framework: Linking Vaccination to Screening Platform in Developing Countries
Dr. Cecilia A. Ladines-Llave, Professor and Chair, Cancer Institute, Million to the University of the Philippines Manila-Philippine General Hospital, Philippines

10:30-10:55

Title: Insight into the Immunological Potential of Adjuvanted HPV Vaccines
Dr. Haiwen Tang, Director, GlaxoSmithKline Biologicals, China

10:55-11:20

Title: Update on Gardasil (Quadrivalent Humanpapillomavirus [HPV] 6/11/16/18 Vaccine) Clinical Trial Efficacy Results
Dr. Randall N. Hyer, Senior Director, Banyu Pharmaceutical Co., LTD(A Subsidiary of Merck and Co., Inc. USA), Japan

11:20-11:45

Title: Trivalent Human Papillomavirus (HPV) VLP Vaccine Covering HPV Type 58 can Elicit High Level of Humoral Immunity but also Induce Interferences among Component Types
Dr. Xuemei Xu, Professor of Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, China

11:45-12:10

Title: Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years
Dr. Rongcheng Li, Professor & Director, CDC Guangxi, China

 Chair:

Dr. Michael O. Favorov, Deputy Director-General; Director of Translational Research Division, International Vaccine Institute, Korea

 Co-Chair:

Dr. Chaoping Chen, Assistant Professor, Colorado State University, USA

13:30-13:55

Title: Can Typhoid be Eliminated
Dr. Michael O. Favorov, Deputy Director-General; Director of Translational Research Division, International Vaccine Institute, Korea

13:55-14:20

Title: Rotavirus Vaccine Trials in Bangladesh: Experience in Phase I to IV Studies
Dr. K. Zaman, Scientist &Epidemiologist, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B)

14:20-14:40

Coffee Break

 Chair:

Dr. Jose M. Galarza, CEO, TechnoVax, Inc., USA

 Co-Chair:

Dr. Xuguang (Sean) Li, Professor, Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada

08:30-08:50

Keynote Speech:
Title: Progress in Pandemic Vaccine Development and Manufacturing
Dr. Oleg I. Kiselev, Academician, Russian Academy of Medical Sciences, Russia

08:50-09:10

Title: Monovalent and Polyvalent Influenza Virus-Like Particles as Effective and Economical Human and Animal Vaccines
Dr. Jose M. Galarza, CEO, TechnoVax, Inc., USA

09:10-09:30

Title:VLP Vaccines in Response to Influenza Pandemic: Preclinical and Clinical Evaluation of a Plant-made VLP Vaccine for H5N1 Strains
Dr. Nathalie Landry, Vice President, Product Development, Medicago Inc, Canada

09:30-09:50

Title: Targeting the Most Conserved Sequences of Virtually All Subtypes of the Influenza A Viral Hemagglutinins
Dr. Xuguang (Sean) Li, Professor, Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada

09:50-10:10

Title: Rational Design of Pandemic Influenza Vaccines
Dr. Honglin Xu, Director, Laboratory of Virology, National Vaccine and Serum Institute, China

10:10-10:30

Coffee Break

10:30-10:50

Title: A Novel Assay for Influenza Virus Quantification Using Surface Plasmon Resonance
Dr. Raf Lemmens, Global Fast Trak Leader, GE Healthcare Life Sciences, Sweden

10:50-11:10

Title:Attenuated Bordetella Pertussis Protects against Influenza A Lethal Challenge by Dampening the Cytokine Storm
Dr Alonso Sylvie, Assistant Professor, Department of Microbiology, Immunology Programme, National University of Singapore, Singapore

 Chair:

Dr. Jose M. Galarza, CEO, TechnoVax, Inc., USA

 Co-Chair:

Dr. Xuguang (Sean) Li, Professor, Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Canada

11:10-11:30

Title: Development of Baculovirus as a New Avian Influenza Vaccine Platform
Dr. Yu-Chen Hu, Professor, National Tsing Hua University, Taiwan

11:30-11:50

Title: Proposal and Method of Artificial Influenza Pandemic by Live Attenuated Infectious Vaccine to Prevent Natural Pandemic H5N1
Dr. Yoshinori Hayakawa, Professor, Toin University of Yokohama, Japan

 Chair:

Dr. Miles Carroll, Head, Health Protection Agency, UK

 Co-Chair:

Dr. Jinling Li, Research Scientist, Medicine & Epidemiology, School of Veterinary Medicine, University of California, Davis, USA

16:40-17:00

Title: Key Immunological Observations from the Clinical Development of Sanofi Pasteur Pandemic Influenza A (H1N1) Vaccines
Dr. Inca C. Kusters, Director External R&D, Sanofi-Pasteur, France

17:00-17:20

Title: Development and Application of Animal Models for the Evaluation of Swine Flu Vaccines.
Dr. Miles Carroll, Head, Health Protection Agency, U.K

17:20-17:40

Title: Genetic Alterations of Hemagglutinin Associated with Species-specific Neuraminidase Stalk Deletions and the Implication in Vaccine Development
Dr. Jinling Li, Research Scientist, Medicine & Epidemiology, School of Veterinary Medicine, University of California, USA

 Chair:

Dr. Eszter Nagy, Senior Vice President, Pre-clinical Research & Development, Intercell AG, Austria

 Co-Chair:

Dr. Kerin Fresa-Dillon, Professor,Department of Pathology, Microbiology, Immunology，Philadelphia College of Osteopathic Medicine, USA

15:30-15:50

Keynote Speech:
Title: A Live Recombinant Attenuated Salmonella Anti-Pneumococcal Vaccine for Newborns
Dr. Roy Curtiss III, Academician, United States National Academy of Sciences, USA

15:50-16:10

Keynote Speech:
Title:Development of a Full Coverage Pneumococcal Vaccine Comprising Highly Conserved Proteins: From Discovery to the First Clinical Trial
Dr. Eszter Nagy, Senior Vice President, Pre-clinical Research & Development, Intercell AG, Austria

16:10-16:30

Title: A New, Single Protein as a Vaccine with Broad Effects for Prevention of Pneumococcal Infections
Dr. Dong-Sheng Chen, President/CEO, Synergy America, Inc., USA

16:30-16:50

Title: Using New Pneumococcal Vaccines in Combination for Maximum Protection
Dr. Amanda J. Leach, Associate Professor, Child Health Division, Menzies School of Health Research, Australia

16:50-17:10

Title: Pneumococcal Conjugate Vaccine-7: Effect on Serotypes/Groups and Antimicrobial Susceptibility of Streptococcus Pneumonia in Kuwait
Dr. Eiman Mokaddas, Professor of Clinical Microbiology, Chairman Microbiology Department, Kuwait University, Kuwait

Chair:

Dr. Jacqueline Shea, General Manager, Oxford-Emergent Tuberculosis Consortium Ltd, UK

 Co-Chair:

Dr. Zhongming Li, President/CEO, Shanghai H&G Biotechnology Inc., China

13:30-13:55

Title: Development of a Live Vaccine (rBCGΔureC: Hly/VPM1002) against Tuberculosis
Dr. Bernd Eisele, CEO of VPM Inc., Germany

13:55-14:20

Title: Development of MVA85A, A Leading Tuberculosis Vaccine Candidate
Dr. Jacqueline Shea, General Manager, Oxford-Emergent Tuberculosis Consortium Ltd, UK

14:20-14:45

Title: Immunotherapy of Multi-drug-resistant (MDR) Mycobacterium Tuberculosis Infected Mice Using DNA Vaccines or in Combination with Chemotherapy
Dr. Zhongming Li, President/CEO, Shanghai H&G Biotechnology Inc., China

14:45-15:10

Title: Subunit Vaccine Combining Multiple Antigens Improves BCG-primed Protective Efficacy against Mycobacterium Tuberculosis Infection in Mice
Dr. Bingdong Zhu, Vice Professor, Lanzhou University, China

15:10-15:30

Coffee Break

15:30-15:55

Title: Development of a New and Improved Recombinant BCG Expressing a Candidate Antigen on the Mcobacterial Surface
Dr. Giovanni Delogu, Professor, Catholic University, Italy

15:55-16:20

Title: Prospects for Post-infection Vaccines and Adding Adjunctive Immunotherapy to Anti-Tuberculosis Chemotherapy
Dr. Douglas B Lowrie (Daoliang Luo), Senior Research Fellow, Fudan University, China

16:20-16:45

Title:Recombinant BCG Vaccine against Tuberculosis
Dr. Honghai Wang,Professor, Fudan University, China

16:45-17:10

Title: In-silico Selected Peptide Antigens from Mycobacterium Tuberculosis: New Perspectives for Vaccine Development
Dr. Fouad Seghrouchni, Chief Engineer, National Institute of Hygiene, Morocco

 Chair:

Dr. Hira Nakhasi, Director, Division of Emerging and Transfusion Transmitted Diseases, OBRR/CBER/FDA, USA

 Co-Chair:

Dr. Donald McManus, Head, Molecular Parasitology Laboratory, Queensland Institute of Medical Research, Australia

13:30-13:50

Keynote Speech:
Title: Can the Current Approach Effectively Conquer Schistosomiasis?
Dr. Robert Bergquist, Editor-in-Chief of Geospatial Health, Sweden

13:50-14:10

Title: Live Attenuated (Genetically Modified) Leishmania Vaccines: Evaluation of Safety and Immunogenicity
Dr. Hira Nakhasi, Director, Division of Emerging and Transfusion Transmitted Diseases, US Food and Drug Administration, USA

14:10-14:30

Title: Mucosal Vaccines for Systemic Leishmaniasis
Dr. Bartira Rossi-Bergmann, Professor, Institute of Biophysics, Federal University of Rio de Janeiro, Brazil

14:30-14:50

Title: Prospects for Development of a Transmission Blocking Vaccine against Schistosoma Japonicum
Dr. Donald McManus, Head, Molecular Parasitology Laboratory, Queensland Institute of Medical Research, Australia

14:50-15:10

Title: Development of a Bivalent Anti Helminth Vaccine against Schistosomiasis and Fascioliasis
Dr. Miriam Tendler, Full Researcher, Oswaldo Cruz Foundation, Brazi

15:10-15:30

Coffee Break

 Chair:

Dr. Joerg Schneider, Senior Director, Emergent BioSolutions, UK

 Co-Chair:

Dr. Xuming Zhang, Professor, Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, USA

15:30-15:50

Title: Development of the MVAtor® Viral Vector Platform
Dr. Joerg Schneider, Senior Director, Emergent BioSolutions, UK

15:50-16:10

Title: An Update on the Development of SARS Vaccines
Dr. Xuming Zhang, Professor, Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, USA

16:10-16:30

Title: Advances in Vaccines against Group B Meningococci
Dr. Xilian Bai, Head, Health Protection Agency Vaccine Evaluation Unit, UK

 Chair:

Dr. Nathalie Garcon, Vice President; Head of Global Adjuvant Center for Vaccines, GlaxoSmithKline Biologicals, Belgium

 Co-Chair:

Dr.Bror Morein, Professor, Uppsala University. Sweden

11:45-12:10

Title: Advocacy Strategies for Recruitment of Volunteers for Phase I HIV Vaccine Trials in Chennai, India
Dr. V. D. Ramanathan, Scientist, Department of Clinical Pathology, Tuberculosis Research Centre, India

 Chair:

Dr. Xia Jin, Associate Professor, University of Rochester School of Medicine and Dentistry, USA

 Co-Chair:

Dr. Dinesh K. Singh, Associate Professor, Norfolk State University, USA

08:30-08:55

Title: Mimics of B-cell Epitopes for Designing of HIV-1 Vaccine Candidates
Dr. Alexander A. Ilyichev, Professor, State Research Center of Virology and Biotechnology Vector, Russia

08:55-09:20

Title: A Novel HIV T Helper Epitope-based Vaccine Elicits Poly-functional HIV-specific CD4+ T Cells in a Phase I Clinical Trial in HIV-uninfected Adults
Dr. Xia Jin, Associate Professor, University of Rochester School of Medicine and Dentistry, USA

09:20-09:45

Title: Trafficking of HIV-1 in Human Dendritic Cells
Dr. Dinesh K. Singh, Associate Professor, Norfolk State University, USA

09:45-10:00

Coffee Break

 Chair:

Dr. Matthew Moyle, Chief Scientific Officer, Theraclone Sciences, Inc, USA

 Co-Chair:

Dr. Catarina E. Hioe, Associate Professor of Pathology, NYU School of Medicine, USA

15:00-15:20

Title: Human Antibodies Identify Highly Conserved Functional Epitopes on HIV-1 and Influenza Viruses
Dr. Matthew Moyle, Chief Scientific Officer, Theraclone Sciences, Inc, USA

15:20-15:40

Title: GBV-C Envelope Glycoprotein 2 (E2) Elicits Antibodies Neutralize HIV Infectivity in Vitro --a Novel HIV Vaccine Candidate?
Dr. Jinhua Xiang, Associate Research Scientist, The University of Iowa & Iowa City VAMC Research, USA

15:40-16:00

Title: Transmitted HIV-1 Variants in HIV Infected Mother-child Pairs, Carrying Different Subtypes
Dr. Anneka Ehrnst, Adjunct Professor, Karolinska Institute, Sweden

 Chair:

Dr. Harriet L. Robinson, Chief Scientific Officer, GeoVax Inc., USA

 Co-Chair:

Dr. Shixia Wang, Associate Professor, University of Massachusetts Medical School, USA

13:30-13:50

Title: Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
Dr. Harriet L. Robinson, Chief Scientific Officer, GeoVax Inc., USA

13:50-14:10

Title: Heterologous Prime-boost HIV Vaccine in Preclinical Animal Studies
Dr.Shixia Wang, Associate Professor of Medicine, Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, USA

14:10-14:30

Title: Phase 1 Preclinical Studies on DNA/MVA Vaccines, Co-expressed GM-CSF, A Strong Adjuvant for Prevention of Acquisition
Dr. Lilin Lai, Research Associate, Emory University, USA

14:30-14:50

Title: A Framework for Assessing Immunological Correlates of Protection in Vaccine Trials
Dr. Li Qin, Assistant Member, Fred Hutchinson Cancer Research Center, USA

14:50-15:00

Coffee Break

 Chair:

Dr. Matthew Moyle, Chief Scientific Officer, Theraclone Sciences, Inc, USA

 Co-Chair:

Dr. Catarina E. Hioe, Associate Professor, NYU School of Medicine, USA

16:00-16:20

Title: Polyepitope Based Approach for Developing Artificial T- and B-Cell Immunogens as HIV-1 Vaccine
Dr. Larisa I. Karpenko, Head, State Research Center of Virology and Biotechnology Vector, Russia

16:20-16:40

Title: Use of Immune Complexes to Enhance Antibody Responses to HIV-1 Neutralizing Epitopes
Dr. Catarina E. Hioe, Associate Professor, NYU School of Medicine, USA

16:40-17:00

Title: Structure-based Design of Immunogens Aiming at the V3 Epitope of HIV-1 gp120
Dr. Xiangpeng Kong, Associate Professor, NYU School of Medicine, USA

17:00-17:20

Title: Lentiviral DNA as HIV-vaccine Candidate
Dr. Dinesh K. Singh, Associate Professor, Norfolk State University, USA

 Chair:

Dr. Jaroslav Michálek, Professor, Masaryk University, Czech Republic

 Co-Chair:

Dr. Peter Gottlieb, Associate Professor, Barbara Davis Center, University of Colorado at Denver School of Medicine, USA

10:30-10:50

Title:Optimized Maturation Coctail for Clinical Grade Dendritic Cell Vaccination
Dr. Jaroslav Michálek, Professor, Masaryk University, Czech Republic

10:50-11:10

Title: Development and Validation of Assays for Vaccine Stability and Batch Release
Dr. Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency, UK

11:10-11:30

Title: Interim Results of a Phase I/II Clinical Trial of a DNA Plasmid Vaccine (BHT-3021) for Type 1 Diabetes
Dr. Peter Gottlieb, Associate Professor, Barbara Davis Center, University of Colorado at Denver School of Medicine, USA

11:30-11:50

Title: A Novel T-cell Independent Liposomal Amyloid-beta Vaccine for the Treatment of Alzheimer’s Disease
Dr. Alberto Silva, Research Scientist, Biology, AC Immune SA, Switzerland

 Chair:

Dr. Giulio Tarro, Professor, Division of Infectious Diseases, D Cotugno Hospital, Italy

 Co-Chair:

Dr. Heng Zhao, Professor, Chinese Academy of Agricultural Sciences, China

08:30-08:55

Title: Tumor Liberated Protein from Cancer and Perspectives for Immunotherapy
Dr. Giulio Tarro, Professor, Division of Infectious Diseases, D Cotugno Hospital, Italy

08:55-09:20

Title: Linking Evidence-based Vaccinology and Economic Analysis in a CPG for Vaccines in Cancer Patients
Dr. Liliana Chicaiza, Associate Professor, National University of Colombia, USA

09:20-09:45

Title: Recombinant Newcastle Disease Virus as a Potential Candidate for CancerTherapy
Dr. Heng Zhao, Professor, Chinese Academy of Agricultural Sciences, China

09:45-10:10

Title: There is More to the Solute Carrier Family 11 Member 1(SLC11A1) than Cytokine Regulation.
Dr. Agnes Abiola Awomoyi, Scientist, Internal Medicine Ohio State University, USA

10:10-10:30

Coffee Break

 Chair:

Dr. Jagat Kanwar, Associate Professor, Institute for Technology Research and Innovation (ITRI), Deakin University, Australia

 Co-Chair:

Dr. Heng Zhao, Professor, Chinese Academy of Agricultural Sciences, China

10:30-10:55

Title: Biotechnology beyond Boundaries, Nanocarriers Delivery of Small Interfering RNA and Micro RNA: Promises of Cancer Gene Therapy
Dr. Jagat Kanwar, Associate Professor, Institute for Technology Research and Innovation (ITRI), Deakin University, Australia

10:55-11:20

Title: Adenoviral Vaccination against Cancer
Dr. Maria Rathmann Sørensen, Postdoc,University of Copenhagen, Denmark

 Chair:

Dr. Barbara Guinn, Senior Research Fellow, University of Southampton, UK

 Co-Chair:

Dr. Jochen Greiner, Professor, University of Ulm, Germany

13:30-13:50

Title:Dendritic Cells: In-vivo Targeting for Improved Anti-cancer Immune Responses
Dr. Yvette van Kooyk, Professor, Department of Molecular Cell Biology and Immunology, VU University Medical Center, The Netherlands

13:50-14:10

Title: A Clinical Trial of Interleukin-13 Receptor Alpha 2 Peptide-pulsed DC Vaccine for Malignant
Gliomas
Dr. Atsushi Natsume, Associate Professor, Nagoya University, Japan

14:10-14:30

Title: Dendritic Cell Vaccination to Improve Adoptive T-cell Transfer in Metastatic Melanoma
Dr. Gregory Lizee, Assistant Professor, University of Texas M.D. Anderson Cancer Center, USA

14:30-14:50

Title: Effective Cancer Vaccination by Adenovirus Gene Therapy Vector and Integrin Expressing Dendritic Cells (DC)
Dr. Saroj K. Basak, Assistant Researcher, University of California Los Angeles, USA

14:50-15:10

Title: Controllable Live Dendritic Cell Vaccine Induce Antitumor Immunity against Ovarian Cancer
Dr. Yu Kang, Research Fellow, Fudan University, China

15:10-15:30

Coffee Break

 Chair:

Dr. Barbara Guinn, Senior Research Fellow, University of Southampton, UK

 Co-Chair:

Dr. Jochen Greiner, Professor, University of Ulm, Germany

15:30-15:50

Keynote Speech:
Title: Transgene’s Therapeutic Vaccines
Dr. Jean-Yves Bonnefoy, Vice-President, Transgene S.A., France

15:50-16:10

16:10-16:30

Title: WT1-targeted Dendritic Cell Vaccination as Post-remission Immunotherapy of Acute Myeloid Leukemia
Dr. Viggo Van Tendeloo, Associate Professor, Vaccine & Infectious Disease Institute, Center for Cellular Therapy & Regenerative Medicine, Antwerp University Hospital, Belgium

16:30-16:50

Title: Preclinical Studies of Carbohydrate Mimetic Peptide Vaccines for Breast Cancer and Melanoma
Dr. Thomas Kieber-Emmons, Professor & Deputy Director, University of Arkansas for Medical Sciences, USA

16:50-17:10

Title: Leukemia-associated Antigens as Target for Vaccination Strategies in AML
Dr. Jochen Greiner, Professor, University of Ulm, Germany

17:10-17:30

Title: Newcastle Disease Virus: A Promising Delivering System for Cancer Immunotherapy
Dr. Haiyan Liu, Professor, Soochow University, China

 Chair:

Dr. Frank J. Malinoski, Chief Medical Officer, Liquidia Technologies, Research Triangle Park,  USA

 Co-Chair:

Dr. Martin Wisher, Senior Scientific Director, BioReliance, UK

13:30-13:55

Title: Vaccine Safety: Pre and Post Licensure Risk Evaluation Management Systems (REMS)
Dr. Frank J. Malinoski, Chief Medical Officer, Liquidia Technologies, Research Triangle Park, USA

13:55-14:20

Title: LC/MS Characterization of Recombinant Protein Vaccine
Dr.Jeffrey Mazzeo, Biopharmaceutical Business Director, Pharmaceutical Market Development, Waters Corporation, USA

14:20-14:45

Title: Vaccination: Is it a Real Problem for Anesthesia and Surgery
Dr. John Currie, Consultant in Paediatric Anaesthesia and Pain Management, Royal Hospital for Sick Children, UK

14:45-15:10

Title: Call Centre Informatics, Focus on Achieving Safe and Efficacious Use of Vaccines
Ms. Susan Halasi, Drug Information Pharmacist, Ontario Pharmacists' Association, Canada

15:10-15:30

Coffee Break

15:30-15:55

Title: Injection Techniques to Reduce Pain during Vaccination in Childhood
Dr. Moshe Ipp, Professor of Paediatrics, University of Toronto, Canada

15:55-16:20

Title: Immunization Administration: Are Our Vaccines Safe and Effective
Dr. Pam Strohfus, Associate Professor, Boise State University, USA

 Chair:

Dr. Frank J. Malinoski, Chief Medical Officer, Liquidia Technologies, Research Triangle Park, USA

 Co-Chair:

Dr. Martin Wisher, Senior Scientific Director, BioReliance, UK

16:20-16:45

Title: Economic Analysis of Vaccines in Immuno-compromised Patients in Middle Income Countries
Dr. Mario Garcia-Molina, Associate Professor, National University of Colombia, USA

 Chair:

Dr. Jovelle B. Laoag-Fernandez, Director, Global Medical Affairs, Adolescent and Adult Vaccines, GlaxoSmithKline Biologicals, Belgium

 Co-Chair:

Dr. Sheng Li, Chief, Biomedical Advanced Research & Development Authority, US Department of Health and Human Services, USA

16:00-16:20

Title: The Time Trade off Approach to Measure Patients’ Preferences for Health States Associated with HPV-related Pathologies: A Multicenter Study Performed in Italy
Dr. Francesco Saverio Mennini, Professor; University of Rome La Sapienza, Italy

16:20-16:40

Title: Increasing Global Access to Vaccinology Know-how and Technology
Dr. Jan Hendriks, Account Manager, Netherlands Vaccine Institute, The Netherlands

16:40-17:00

Title: Immune Response to Aerosolized MMR Vaccine in Adults
Dr. Jose-Luis Diaz Ortega, Medical Investigator, National Institute of Public Health, Mexico

17:00-17:20

Title: Preparation for a Pandemic Flu
Dr. Nada Milic, Senior Advisor, Center for Prevention and Control Disease Institute of Public Health of Serbia, Serbia

 Chair:

Dr. Carol Sabourin, Chief Scientist of Battelle Science and Technology & Senior Research Leader of National Security Global Business, Battelle Memorial Institute , USA

 Co-Chair:

Dr. Lanling Zou, Bacteriology Program Officer & Chief Translational Sciences Section, BMB/DMID/NIAID/NIH/DHHS, USA

13:30-13:50

Title: Animal Models to Evaluate Vaccine Efficacy for Infectious Diseases under the Animal Rule
Dr. Carol Sabourin, Chief Scientist of Battelle Science and Technology & Senior Research Leader of National Security Global Business, Battelle Memorial Institute , USA

13:50-14:10

Title: Biodefense Effort at NIAID
Dr. Lanling Zou, Bacteriology Program Officer & Chief Translational Sciences Section, BMB/DMID/NIAID/NIH/DHHS, USA

14:10-14:30

Title: BALB/C Mouse Antibody Responses to Ricin Toxin
Dr. John W. Cherwonogrodzky, Scientist, Defence Research and Development Canada – Suffield, Canada

14:30-14:40

Coffee Break

 Chair:

Dr. Jovelle B. Laoag-Fernandez, Director, Global Medical Affairs, Adolescent and Adult Vaccines, GlaxoSmithKline Biologicals, Belgium

 Co-Chair:

Dr. Sheng Li, Chief, Biomedical Advanced Research & Development Authority, US Department of Health and Human Services, USA

14:40-15:00

Title:Lessons Learned on Models of Delivery for HPV Vaccines in Developing Countries: Initial Experiences from the GARDASIL® Access Program
Dr. Joseph Saba, CEO, AXIO, France

15:00-15:20

Title: New Perspectives for Vaccine Development: the Value of Adjuvantation
Dr. Haiwen Tang, Director, GlaxoSmithKline Biologicals, China

15:20-15:40

Title: Funding New Technologies for the Development of Seasonal and Pandemic Influenza Vaccines
Dr. Sheng Li, Chief, Biomedical Advanced Research & Development Authority, US Department of Health and Human Services, USA

15:40-16:00

Title: 30 Years Experience in the Use of Aerosol Route for Viral Vaccines
Dr. Jorge Fernández de Castro P., External Consultant, Felipe Ochoa y Asociados, S.C., Mexico

 Chair:

Dr. Andrew Potter, Director& CEO, VIDO/InterVac, Canada

 Co-Chair:

Dr. Scott McVey, Professor& Director, University of Nebraska, USA

08:30-08:50

Keynote speech:
Title: Development of Vaccines for the Control of Foodborne Zoonotic Pathogens
Dr. Andrew Potter, Director& CEO, VIDO/InterVac, Canada

08:50-09:10

Title: Comparative Evaluation of Vaccination Strategies against Streptococcus Suis Infections in Swine
Dr. Christoph Georg Baums, Professor, Institute for Microbiology, Tieraerztliche Hochschule Hannover, Germany

09:10-09:30

Title: Quality Standards for Foot-and-mouth Disease (FMD) Vaccine: The Key Role of Highly Purified Antigens
Dr. Rodolfo Bellinzoni, Director of Operations, Biogénesis Bagó S.A, Argentina

09:30-09:50

Title: The development of DNA Vaccine and Adjuvant against Actinobacillus Pleuropneumoniae
Dr. WenJen Yang, Assistant Professor, National University of Kaohsiung, Taiwan

09:50-10:10

Title:Gentamicin-attenuated Leishmania Infantum: Production of a Cellular Immune Response and Protection against Experimental Visceral Leishmaniasis Infection in Dogs
Dr.Hamid Daneshvar, Head of Department of Molecular Immunology, Medical School of Kerman University, Iran

10:10-10:30

Coffee Break

10:30-10:50

Title: Virus- and Cell-based Cancer Vaccines for Agricultural and Companion Animals
Dr. Mark S. Parcells, Professor, University of Delaware, USA

10:50-11:10

 Chair:

Dr. Andrew Potter, Director& CEO, VIDO/InterVac, Canada

 Co-Chair:

Dr. Scott McVey, Professor& Director, University of Nebraska, USA

11:10-11:30

Title: Genetic and Antigenic Variation among Mannheimia Haemolytica Isolates of the Bovine Respiratory Tract
Dr. Scott McVey, Professor& Director, University of Nebraska, USA

11:30-11:50

Title:Novel Vaccine Strategies to Control E. coli O157: H7 in Cattle
Dr. Arvind Mahajan, Group Leader, The Roslin Institute,  Royal (Dick) School of Veterinary Studies, University of Edinburgh, UK

11:50-12:10

Title: The Reduction of Mortality Rate in a Goat Breeding Farm in Sabah by Inactivated Recombinant Vaccine
Dr. M.Y. Sabri, Senior Lecturer, University Putra Malaysia, Malaysia

 Chair:

Dr. Phillip Harry Klesius, Supervisory Microbiologist & Research Leader, United States Department of Agriculture-Agriculture Research Service (USDA-ARS), USA

 Co-Chair:

Dr. Julia W. Pridgeon, Research Molecular Biologist, United States Department of Agriculture-Agriculture Research Service (USDA-ARS), USA

08:30-08:55

Title: Fish Vaccines – Current Status and Future Challenges
Dr. Roar Gudding, Deputy Director, National Veterinary Institute, Norway

08:55-09:20

Title: Molecular Approaches for Development of Vaccines against Intracellular Fish Pathogens
Dr. Audun H. Nerland, Professor, Institute of Marine Research and University of Bergen, Norway

09:20-09:45

Title: Streptococcus Iniae Vaccine
Dr. Phillip Harry Klesius, Supervisory Microbiologist & Research Leader, United States Department of Agriculture-Agriculture Research Service (USDA-ARS), USA

09:45-10:10

Title: Identification of Upregulated Genes in a Modified Live Vaccine Strain of Edwardsiella Ictaluri Compared to a Virulent Parent Strain and Characterization of Novel DNA Vaccine Candidates
Dr. Julia W. Pridgeon, Research Molecular Biologist, United States Department of Agriculture-Agriculture Research Service (USDA-ARS), USA

10:10-10:35

Title: Bacterial Fish Vaccines - Development, Production and Use
Dr. Nina Sandlund, Scientist, Institute of Marine Research, Norway

 Chair:

Dr. Jonathan Liu, Director of R& D, Vaccine Development, MedImmune, USA

 Co-Chair:

Dr. Andrew Malloy, Head, NanoSight Ltd., UK

08:30-08:55

Keynote Speech:
Title: The Biosecurity, Production, And Quality Control of Specific Pathogen Free (SPF) Eggs for Vaccine Production
Dr. Theodore Girshick, Director of Laboratory Operations, Charles River Avian Products and Services, USA

08:55-09:20

Title: International Regulations for Vaccine Manufacturing: Perspectives on WHO, EU and FDA Expectations
Dr. Scott M. Wheelwright, President, Strategic Manufacturing Worldwide, Inc., USA

09:20-09:45

Title: Application of Process Analytic Technology (PAT) in Vaccine Development: Using Modern Technologies to Develop Modern Vaccines
Dr. Jonathan Liu, Director of R&D, Vaccine Development, MedImmune, USA

09:45-10:10

Title: Industrial Purification Platform for Various Flu and Flu like Particles
Dr. Charles M. Y. Lim, Vice President Asia Region, BIA Separations, Austria

10:10-10:30

Coffee Break

10:30-10:55

Title: Direct and Real-time Sizing and Counting of Viruses and VLPs in Liquids.
Dr. Andrew Malloy, Head, NanoSight Ltd., UK

10:55-11:20

Title: Sabin-IPV Development for Technology-transfer Purposes: Initial Process Development and Clinical Lot Production
Dr. Wilfried A. M. Bakker, Senior Scientist Viral Vaccines & Project Leader, Netherlands Vaccine Institute, The Netherlands

11:20-11:45

Title: New Continuous Cell Substrates for Vaccine Production: Development of New Assays to Detect Potential Contaminants
Dr. Martin Wisher, Senior Director, BioReliance, UK

11:45-12:10

Title: Foot-and-mouth Disease (FMD) Vaccine Production: From a Local Market Supplier to a Major International Player; A South American Experience.
Dr. Rodolfo Bellinzoni, Director of Operations, Biogénesis Bagó S.A, Argentina

Chair:

Dr. Guohua Yue, President&CEO, Antagen Biosciences, Inc., USA

13:30-13:55

Title: High-performance Mammalian Cell Expression System for Commercial Production of Therapeutic Proteins
Dr. Guohua Yue, President& CEO, Antagen Biosciences, Inc., USA

13:55-14:20

Title: Suspension-VERO Cell Cultures for the Production of Viral Vaccines for Human Use
Dr. Marina Etcheverrigaray, Professor at the Universidad Nacional del Litoral & Research Member of the National Research Council, Argentina

14:20-14:45

Title: Baculovirus-silkworm Multigene Expression Platform for Production of Virus –like Particles Vaccine Efficiently and Economically
Dr. Lunguang Yao, Vice Dean, Nanyang Normal University, China

Chair:

Dr. Guohua Yue, President& CEO, Antagen Biosciences, Inc., USA

14:45-15:10

Title: DNA Vaccine Purification Process, A Scale-up Study
Dr. Yongjian Zheng, Lead Application Scientist, GE Healthcare Life Sciences, China

15:10-15:30

Coffee Break